Cytek Biosciences, Inc. CTKB Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $31.81M+9.7% | $28.98M-68.9% | $93.28M+23.6% | $75.47M-20.8% | $95.3M-3.5% | ||
| $227.28M-1.4% | $230.4M+0.8% | $228.48M+1.8% | $224.48M+5.4% | $212.89M+2.3% | ||
| $199.36M+2.3% | $194.91M+2.4% | $190.38M+2.6% | $185.53M-0.3% | $186.11M-4.8% | ||
| $379.3M-3.2% | $392M+0.9% | $388.49M+1.5% | $382.83M+0.6% | $380.5M-4.0% | ||
| $20.47M+13.7% | $18.01M-0.2% | $18.05M-1.7% | $18.35M+2.9% | $17.83M-0.7% | ||
| $16.69M0.0% | $16.7M0.0% | $16.7M-0.1% | $16.71M+0.2% | $16.68M+0.1% | ||
| $15.7M-6.6% | $16.82M-4.8% | $17.68M-5.0% | $18.6M-4.3% | $19.43M-3.5% | ||
| $449.11M-2.7% | $461.54M-6.7% | $494.92M+0.3% | $493.32M+2.2% | $482.6M-3.4% | ||
| $27.64M+1.8% | $27.14M+3.4% | $26.26M+9.3% | $24.02M+18.0% | $20.36M+14.1% | ||
| $30.03M+5.4% | $28.5M+74.7% | $16.32M-1.9% | $16.63M+5.8% | $15.72M-2.4% | ||
| $80.94M+4.0% | $77.8M+3.5% | $75.21M+2.6% | $73.27M+8.2% | $67.69M0.0% | ||
| $386K-26.5% | $525K-19.8% | $655K-17.2% | $791K-13.8% | $918K-12.6% | ||
| $121.47M+1.4% | $119.8M+3.0% | $116.35M+0.5% | $115.76M+12.4% | $102.97M-0.8% | ||
| 1B0.0% | 1B+781,150% | 128K+0.8% | 127K-0.8% | 128K-0.8% | ||
| -$120.6M-18.5% | -$101.74M-76.4% | -$57.66M-10.5% | -$52.18M-12.0% | -$46.6M-32.4% | ||
| $327.64M-4.1% | $341.74M-9.7% | $378.57M+0.3% | $377.56M-0.5% | $379.62M-4.1% | ||
| $449.11M-2.7% | $461.54M-6.7% | $494.92M+0.3% | $493.32M+2.2% | $482.6M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cytek Biosciences, Inc.'s total assets?
- Cytek Biosciences, Inc. (CTKB) holds $449.1M in total assets, down 6.9% year over year.
- How much debt does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. carries $16.8M in total debt against $327.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. holds $31.8M in cash and equivalents.
- Can Cytek Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 4.69 — current assets exceed current liabilities.
- Where does Cytek Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
